Tobias Dechow

2.9k total citations
73 papers, 2.0k citations indexed

About

Tobias Dechow is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Tobias Dechow has authored 73 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Tobias Dechow's work include Gastric Cancer Management and Outcomes (15 papers), Lung Cancer Treatments and Mutations (14 papers) and Medical Imaging Techniques and Applications (10 papers). Tobias Dechow is often cited by papers focused on Gastric Cancer Management and Outcomes (15 papers), Lung Cancer Treatments and Mutations (14 papers) and Medical Imaging Techniques and Applications (10 papers). Tobias Dechow collaborates with scholars based in Germany, United States and Austria. Tobias Dechow's co-authors include Ken Herrmann, Andreas K. Buck, Christian Peschel, Laura Pedranzini, Jacqueline Bromberg, Markus Schwaiger, Bernd J. Krause, William L. Gerald, Irina Linkov and Hans‐Jürgen Wester and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Tobias Dechow

70 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tobias Dechow Germany	24	793	692	475	463	358	73	2.0k
Wael A. Harb United States	23	1.4k 1.8×	923 1.3×	759 1.6×	273 0.6×	247 0.7×	118	2.5k
Todd Hembrough United States	25	880 1.1×	942 1.4×	524 1.1×	149 0.3×	293 0.8×	71	2.3k
Morten Mau‐Sørensen Denmark	28	1.2k 1.5×	1.1k 1.6×	527 1.1×	187 0.4×	310 0.9×	130	2.7k
Peter Ho United States	23	780 1.0×	1.1k 1.6×	354 0.7×	194 0.4×	302 0.8×	48	2.0k
Yutaka Kawakami Japan	22	915 1.2×	777 1.1×	409 0.9×	149 0.3×	319 0.9×	37	2.4k
M. S. Berger United States	19	948 1.2×	857 1.2×	316 0.7×	373 0.8×	122 0.3×	37	2.1k
Yasuhito Terui Japan	31	1.0k 1.3×	709 1.0×	287 0.6×	155 0.3×	817 2.3×	126	2.4k
Leslie B. Lee United States	13	790 1.0×	1.0k 1.5×	988 2.1×	135 0.3×	196 0.5×	13	2.3k
Tiffany K. Ricks United States	15	781 1.0×	542 0.8×	206 0.4×	450 1.0×	84 0.2×	21	1.8k
Arlene Berman United States	22	1.3k 1.6×	614 0.9×	474 1.0×	284 0.6×	138 0.4×	47	2.4k

Countries citing papers authored by Tobias Dechow

Since Specialization

Citations

This map shows the geographic impact of Tobias Dechow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobias Dechow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobias Dechow more than expected).

Fields of papers citing papers by Tobias Dechow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobias Dechow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobias Dechow. The network helps show where Tobias Dechow may publish in the future.

Co-authorship network of co-authors of Tobias Dechow

This figure shows the co-authorship network connecting the top 25 collaborators of Tobias Dechow. A scholar is included among the top collaborators of Tobias Dechow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobias Dechow. Tobias Dechow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lorenzen, Sylvie, Claudia Pauligk, Eray Goekkurt, et al.. (2023). Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer. 23(1). 561–561. 5 indexed citations

Muendlein, Axel, Kathrin Geiger, Christine Heinzle, et al.. (2023). Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients. Journal of Cancer Research and Clinical Oncology. 149(9). 6435–6444. 5 indexed citations

Muendlein, Axel, Christine Heinzle, Eva Maria Brandtner, et al.. (2023). Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer. Oncology Research and Treatment. 46(4). 151–156. 5 indexed citations

Potthoff, Karin, Tobias Dechow, Sylvie Lorenzen, et al.. (2023). SAPHIR: real-world clinical research platform for molecular testing, treatment, and clinical and patient-reported outcomes in patients with gastroesophageal cancer in Germany. SHILAP Revista de lepidopterología. 2. 100007–100007. 2 indexed citations

Decker, Thomas, et al.. (2022). Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors. Oncology Research and Treatment. 45(5). 248–253. 3 indexed citations

Muendlein, Axel, Kathrin Geiger, Tobias Dechow, et al.. (2021). Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. Scientific Reports. 11(1). 6761–6761. 17 indexed citations

Dechow, Tobias, Jorge Riera‐Knorrenschild, Björn Hackanson, et al.. (2021). First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study. Cancer Medicine. 10(22). 8127–8137. 1 indexed citations

Pauligk, Claudia, Peter Thuss‐Patience, Jorge Riera‐Knorrenschild, et al.. (2020). 1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO. Annals of Oncology. 31. S908–S908. 6 indexed citations

Kasper, Stefan, Ralf‐Dieter Hofheinz, Sebastian Stintzing, et al.. (2020). 438P Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO. Annals of Oncology. 31. S427–S428. 1 indexed citations

10.

Graf, Nicolas, Zhoulei Li, Ken Herrmann, et al.. (2015). Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [<sup>18</sup>F]Fluorothymidine-PET. 5(2). 17–28. 1 indexed citations

11.

Li, Zhoulei, Nicolas Graf, Ken Herrmann, et al.. (2012). FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy. Cancer Research. 72(19). 5014–5024. 30 indexed citations

12.

Herrmann, Ken, Andreas K. Buck, Tibor Schuster, et al.. (2011). Predictive Value of Initial¹⁸F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment. Journal of Nuclear Medicine. 52(5). 690–696. 55 indexed citations

13.

Seidl, Stefan, Lars Michel, Katja Specht, et al.. (2010). ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non–Small Cell Lung Cancer. Cancer Research. 70(13). 5368–5378. 85 indexed citations

14.

Buck, Andreas K., Ken Herrmann, Tom Stargardt, et al.. (2010). Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. Journal of Nuclear Medicine Technology. 38(1). 6–17. 86 indexed citations

15.

Herrmann, Ken, Bernd J. Krause, Ralph A. Bundschuh, Tobias Dechow, & Markus Schwaiger. (2009). Monitoring Response to Therapeutic Interventions in Patients With Cancer. Seminars in Nuclear Medicine. 39(3). 210–232. 28 indexed citations

16.

Gorantla, Sivahari Prasad, Tobias Dechow, Rebekka Grundler, Christian Peschel, & Justus Duyster. (2008). Molecular Mechanisms of JAK2V617F Oncogenic Activation: The JAK2- V617F Mutant Utilizes the SH2 Domain for Constitutive Kinase Activity in the Presence of Unstimulated Heterodimeric Cytokine Receptor.. Blood. 112(11). 175–175. 2 indexed citations

17.

Horn, T., Michael Kremer, Tobias Dechow, et al.. (2007). Koch, I.*, Slotta-Huspenina, J.*, Hollweck, R.*, Anastasov, N., Hofler, H.*, Quintanilla-Martinez, L., Fend, F.*: Real-time quantitative RT-PCR shows variable, assay-dependent sensitivity to formalin fixation : Implications for direct comparison of transcript levels in paraffin-embedded tissues. Diagn. Mol. Pathol. 15, 149-156 (2006). 15 indexed citations

18.

Pedranzini, Laura, Tobias Dechow, Marjan Berishaj, et al.. (2006). Pyridone 6, A Pan-Janus–Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells. Cancer Research. 66(19). 9714–9721. 133 indexed citations

19.

Ringshausen, Ingo, Tobias Dechow, Folker Schneller, et al.. (2004). Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia. 18(12). 1964–1970. 54 indexed citations

20.

Dechow, Tobias, Laura Pedranzini, Kenneth Leslie, et al.. (2004). Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proceedings of the National Academy of Sciences. 101(29). 10602–10607. 215 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact